Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimicotinib in combination with chemotherapy and Toripalimab for advanced pancreatic cancer
NCT06111274Phase 2Recruiting
- Sponsor
- Abbisko Therapeutics
- Start
- Oct 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pimicotinib in pancreatic cancer (PC) (2 arms), sponsored by Abbisko Therapeutics. Primary endpoints: Safety Event Occurance and Objective Response Rate. Started Oct 2023; status: recruiting.
02
Drugs
pimicotinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06111274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06111274.